University Children's Hospital Ljubljana, Ljubljana, Slovenia.
Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aikten Building, University of Birmingham, Birmingham, United Kingdom.
Radiol Oncol. 2022 Aug 14;56(3):380-389. doi: 10.2478/raon-2022-0027.
The aim of the study was to investigate long-term risk and spectrum of subsequent neoplasm (SN) in childhood cancer survivors and to identify how trends in therapy influenced cumulative incidence of SN.
The population-based cohort comprises 3271 childhood cancer patients diagnosed in Slovenia aged ≤ 18 years between 1st January 1961 and 31st December 2013 with a follow-up through 31st December 2018. Main outcome measures are standardised incidence ratios (SIRs), absolute excess risks (AERs), and cumulative incidence of SN.
After median follow-up time of 21.5 years for 5-year survivors, 230 patients experienced 273 SN, including 183 subsequent malignant neoplasm (SMN), 34 meningiomas and 56 nonmelanoma skin cancers. 10.5% patients received radiotherapy only, 31% chemotherapy only, 26.9% a combination of chemotherapy and radiotherapy and 16.1% surgery only. The overall SIR was almost 3 times more than expected (SIR 2.9), with survivors still at 2-fold increased risk after attained age 50 years. The observed cumulative incidence of SMN at 30-year after diagnosis was significantly lower for those diagnosed in 1960s, compared with the 1970s and the 1980s (P heterogeneity < 0.001). Despite reduced use of radiotherapy over time, the difference in cumulative incidence for the first 15 years after diagnosis was not significant for patients treated before or after 1995 (p = 0.11).
Risks of developing a SMN in this study are similar to other European population-based cohorts. The intensity of treatment peaked later and use of radiotherapy declined slower compared to high income countries, making continuous surveillance even more important in the future.
本研究旨在探讨儿童癌症幸存者的长期风险和后续新发肿瘤(SN)谱,并确定治疗趋势如何影响 SN 的累积发生率。
该基于人群的队列包括 3271 名在斯洛文尼亚诊断为年龄≤18 岁的儿童癌症患者,诊断日期为 1961 年 1 月 1 日至 2013 年 12 月 31 日,随访至 2018 年 12 月 31 日。主要观察指标是标准化发病比(SIRs)、绝对超额风险(AERs)和 SN 的累积发生率。
在 5 年幸存者的中位随访时间为 21.5 年后,230 名患者经历了 273 例 SN,包括 183 例后续恶性肿瘤(SMN)、34 例脑膜瘤和 56 例非黑色素瘤皮肤癌。10.5%的患者仅接受放疗,31%的患者仅接受化疗,26.9%的患者接受化疗和放疗联合治疗,16.1%的患者仅接受手术治疗。总体 SIR 是预期的近 3 倍,幸存者在达到 50 岁后仍有 2 倍的风险增加。与 20 世纪 70 年代和 80 年代相比,诊断于 20 世纪 60 年代的患者,30 年后诊断的 SMN 累积发生率明显较低(异质性 P < 0.001)。尽管随着时间的推移放疗的使用减少,但在 1995 年之前或之后接受治疗的患者,在诊断后前 15 年的累积发病率差异无统计学意义(p = 0.11)。
本研究中 SMN 的发病风险与其他欧洲基于人群的队列相似。治疗强度较晚达到高峰,放疗的使用下降速度较慢,这使得未来的连续监测更加重要。